multivariate analysis

Related by string. Multivariate analysis * Multivariate . multi variate : multivariate analyzes . vitro diagnostic multivariate . multivariate logistic regression . multivariate regression analysis / analy sis . ANALYSIS . Analysis : Strategic Analysis Review . Chart Analysis News . Electronic Document Analysis * Multivariate analysis showed . Multivariate analysis revealed *

Related by context. All words. (Click for frequent words.) 77 multivariate analyzes 75 univariate analysis 75 covariates 74 multivariable analysis 71 univariate 71 multivariate logistic regression 70 logistic regression analysis 69 multivariate Cox 68 covariate 67 logistic regression model 67 logistic regression 67 Univariate analysis 66 Multivariate analysis 66 multiple logistic regression 66 comorbidity 65 multivariate adjustment 65 potential confounders 65 logistic regression analyzes 65 multivariable logistic regression 64 univariate analyzes 63 Kaplan Meier analysis 63 regression analyzes 63 Univariate 63 conditional logistic regression 63 multivariable analyzes 63 P = .# 63 logistic regression models 62 Subgroup analyzes 62 Logistic regression 62 confounders 62 lymphovascular invasion 62 biochemical recurrence 62 prognostic factors 62 % CI #.#-#.# [002] 62 multivariate regression analysis 62 Logistic regression analysis 61 sociodemographic 61 multivariable 61 comorbidities 61 bivariate 61 proportional hazards 61 nodal metastases 61 % CI #.#-#.# [006] 60 confidence interval CI 60 stepwise logistic regression 60 ANOVA 60 Poisson regression 60 Subgroup analysis 60 subgroup analyzes 60 MetS 60 colorectal adenoma 60 CC genotype 59 tertile 59 highest tertile 59 advanced neoplasia 59 multivariable Cox 59 SNP rs# [002] 59 multivariate 59 lymph node metastasis 59 F FDG PET 59 sociodemographic characteristics 59 Multivariate analyzes 59 confounding variables 59 multivariate regression 59 bivariate analyzes 58 SLNB 58 prostate cancer CaP 58 Multivariate logistic regression 58 mRNA expression 58 LV dysfunction 58 tertiles 58 IPAH 58 bivariate analysis 58 confidence intervals CIs 58 clinicopathological 58 TT genotype 58 n = 58 MMSE score 58 IL#B 58 statistically significant 58 endometrial thickness 58 prognostic factor 58 pT3 58 nonsignificant 58 nonfatal MI 58 logistic regressions 58 posttreatment 58 obstructive coronary artery 58 liver transplant recipients 58 nonparametric 58 sociodemographic factors 58 tumor histology 58 p = .# [002] 58 linear regression analyzes 58 preoperative 58 intima media thickness 58 nodal metastasis 58 scintigraphic 58 Multiple logistic regression 58 prospective cohort 57 confidence interval #.#-#.# 57 meta regression 57 proband 57 tHcy 57 heterozygotes 57 serum concentrations 57 Kaplan Meier curves 57 genotypic resistance 57 bone scintigraphy 57 rheumatoid factor 57 rs# [001] 57 breast carcinoma 57 % CI #.#-#.# [007] 57 generalized estimating 57 advanced adenoma 57 HOMA IR 57 preoperative PSA 57 lowest tertile 57 carotid IMT 57 Bonferroni correction 57 prognostic significance 57 distant metastasis 57 immunohistochemical analysis 57 seminal vesicle invasion 57 mammographic density 57 PCa 57 regression analysis 57 APOE genotype 57 predictor variables 57 atypical hyperplasia 57 Kaplan Meier method 57 lymph node involvement 57 CI = 57 multivariable adjusted 57 Kruskal Wallis test 57 retrospective cohort 56 % CI #.#-#.# [003] 56 comorbid conditions 56 PSADT 56 parous women 56 -#.# ± [002] 56 symptomatic VTE 56 histopathologic examination 56 postintervention 56 odds ratios ORs 56 CYP#D# genotype 56 Kaplan Meier survival 56 pT2 56 rs# [004] 56 intraobserver 56 neoadjuvant chemotherapy 56 multiple linear regression 56 histopathological 56 rs# [003] 56 locoregional recurrence 56 urodynamic 56 immunohistochemical 56 p = #.# [002] 56 rs# [002] 56 histopathologic 56 MDRD 56 microvessel density 56 androgen suppression 56 biochemical relapse 56 explanatory variables 56 retrospective cohort study 56 clinicopathological features 56 statistically significant differences 56 SNP rs# [001] 56 familial aggregation 56 Regression analyzes 56 histopathologic diagnosis 56 gene polymorphisms 56 carotid intima media 56 % CI #.#-#.# [008] 56 endometrial carcinoma 56 nondiabetic patients 56 histologic 56 NMIBC 56 EQ 5D 56 prospectively defined 56 sociodemographic variables 56 locoregional 55 regression coefficient 55 strongest predictor 55 distant metastases 55 lymph node metastases 55 plasma pharmacokinetics 55 colorectal neoplasia 55 genetic polymorphisms 55 multivariable adjustment 55 Immunohistochemical analysis 55 adenotonsillectomy 55 pretransplant 55 preoperative chemotherapy 55 Linear regression 55 euthyroid 55 fasting insulin 55 interobserver reliability 55 interobserver 55 SLN biopsy 55 coronary calcification 55 subscales 55 CaP 55 CVD mortality 55 transvaginal sonography 55 unfavorable prognostic 55 Bonferroni 55 seropositivity 55 symptomatic intracerebral hemorrhage 55 adenoma recurrence 55 extensive metabolizers 55 immunostaining 55 LV ejection fraction 55 ultrasonographic 55 plasma cortisol 55 hsCRP levels 55 confounding factors 55 intact parathyroid hormone 55 NHANES III 55 airway responsiveness 55 ABCB1 55 colorectal neoplasms 55 gallstone disease 55 transabdominal 55 QTc prolongation 55 serum PSA 55 posttransplant 55 micrometastasis 54 TRUS biopsy 54 residual confounding 54 Postoperative 54 coinfected patients 54 esophageal carcinoma 54 angiographically 54 histologic subtype 54 immunohistochemical staining 54 clinico pathological 54 histologically proven 54 lymphadenectomy 54 axillary lymph node 54 variance ANOVA 54 ADRB2 54 virological response 54 PSA nadir 54 adenomatous polyps 54 radiotherapy RT 54 allele frequencies 54 FDG-PET/CT 54 Histologic 54 normotensive 54 nonfatal myocardial infarction 54 rCBF 54 cerebral microbleeds 54 spirometric 54 adjuvant radiotherapy 54 periprocedural 54 linear regression analysis 54 transrectal ultrasound guided 54 autonomic dysfunction 54 potential confounding variables 54 core needle biopsies 54 allelic 54 clinicopathologic 54 MTHFR 54 familial clustering 54 eosinophil count 54 eptifibatide 54 NIHSS score 54 Mantel Haenszel 54 contralateral 54 carotid artery thickness 54 TRUS 54 HNSCC 54 FEV ^ sub 54 meta analytic 54 serum cortisol 54 serum estradiol 54 postoperative complication 54 binary logistic regression 54 radical nephrectomy 54 prognostic variables 54 adrenalectomy 54 statistically nonsignificant 54 pCR 54 advanced adenomas 54 ANCOVA 54 hip BMD 54 beta blocker therapy 54 inotropic 54 polymorphism 54 gadolinium enhanced 54 hydronephrosis 54 homozygotes 54 HRCT 54 subscale scores 54 TURBT 54 coronary stenosis 54 MR spectroscopy 54 papillary thyroid carcinoma 54 SUVmax 54 prespecified secondary 54 neoadjuvant 54 umbilical artery 54 hormone receptor status 54 adenoma 54 prospective multicenter study 54 mediastinal 54 histological subtype 54 postoperative AF 54 cTnI 54 estrogen receptor ER 54 histologically confirmed 54 mucinous 54 prostate carcinoma 54 node metastases 54 demographic variables 54 promoter methylation 54 inhibin B 53 perioperative complications 53 extracapsular extension 53 pretest probability 53 histologically 53 HER2 expression 53 carotid plaques 53 immunoreactivity 53 HRQOL 53 serum cotinine levels 53 cystatin C 53 cellularity 53 incomplete revascularization 53 CR nPR 53 NNRTI resistance 53 Multivariable logistic regression 53 genotypic 53 Secondary endpoints included 53 estimated GFR 53 albumin excretion rate 53 p = 53 lowest quintile 53 Brief Psychiatric 53 radical prostatectomy RP 53 perioperative morbidity 53 postoperative radiotherapy 53 chi squared 53 serum markers 53 virologic failure 53 ^ sup 53 postoperative complications 53 metabolite concentrations 53 β blockers 53 nephrectomy 53 T2DM 53 progesterone receptor PR 53 estimated glomerular filtration 53 hepatocellular carcinomas 53 C#BL/#J mice 53 BMD measurements 53 RRM1 53 lung metastases 53 underwent radical prostatectomy 53 sleeve lobectomy 53 KIF6 carriers 53 adiponectin concentrations 53 hypertensives 53 transient elastography 53 sarcomatoid 53 conventional coronary angiography 53 creatinine ratio 53 definite stent thrombosis 53 ECG abnormalities 53 D dimer 53 Hemodynamic 53 probands 53 platelet reactivity 53 specific antigen PSA 53 statistically significant predictor 53 unmeasured confounders 53 CIN2 + 53 EuroSCORE 53 coronary artery calcification 53 etiologic 53 elevated LDH 53 TOP2A 53 subclinical atherosclerosis 53 femoral neck fracture 53 p = #.# [003] 53 susceptibility loci 53 proteinuria 53 heterozygous 53 reinfarction 53 premenopausal 53 highest quintile 53 RASSF1A 53 parenchymal 53 radical cystectomy 53 COMT genotype 53 adnexal mass 53 tirofiban 53 FDG PET 53 comorbid 53 IDH1 mutation 53 psychiatric comorbidity 53 confounder 53 Pearson correlation coefficients 53 statistically significant correlation 53 postdischarge 53 cytologic 53 atherosclerotic lesion 53 HER2 amplification 53 invasive ductal 53 thiopurine 53 BMI z 53 invasive carcinomas 53 color Doppler sonography 53 PON1 53 Meta analyzes 52 anti Mullerian hormone 52 obstructive CAD 52 iodixanol 52 TMPRSS2 ERG fusion 52 genotype 52 thyrotropin levels 52 patients undergoing CABG 52 alexithymia 52 axillary node 52 parasitaemia 52 pathologic 52 CsA 52 % Confidence Interval 52 thromboembolism 52 morphologic 52 methacholine challenge 52 strongest predictors 52 plasma adiponectin 52 ertapenem 52 cystectomy 52 fig. S4 52 depressive symptomatology 52 noncarriers 52 #F FDG PET 52 CYP#D# inhibitor 52 Glomerular filtration rate 52 serum albumin 52 Secondary endpoints include 52 echocardiographic 52 operable breast cancer 52 AMOR IPAT 52 posttest 52 NSTE ACS 52 prevalences 52 intravesical therapy 52 anthropometric measurements 52 postop 52 mL/min/#.# m 2 52 creatinine levels 52 poststroke 52 Serum concentrations 52 preintervention 52 detrusor overactivity 52 coronary artery calcium 52 thyroid carcinoma 52 laterality 52 52 coronary revascularization 52 adenomatous 52 ipsilateral 52 subclinical hypothyroidism 52 intima media thickness IMT 52 Rating Scale BPRS 52 systolic BP 52 prostate cancer PCa 52 transgene expression 52 nomograms 52 oncologic outcomes 52 nonmetastatic 52 sentinel lymph node biopsy 52 MACCE 52 sonographically guided 52 convergent validity 52 covariance 52 SE alleles 52 noncardiac 52 clinically localized prostate 52 carotid atherosclerosis 52 TIMP 1 52 urothelial carcinoma 52 thyroglobulin 52 bioavailable testosterone 52 invasive lobular 52 karyotypes 52 metabolic parameters 52 depressive symptoms 52 AST ALT 52 nonrandomized 52 cerebral angiography 52 fasting serum 52 chlamydial 52 pancreatic adenocarcinoma 52 Preoperatively 52 doxorubicin docetaxel 52 arteriolar 52 retrospective observational study 52 hierarchical clustering 52 TEAEs 52 nonobese 52 contralateral breast cancer 52 lymphocyte count 52 paclitaxel eluting stents 52 ATACAND 52 inotropic agents 52 left ventricular LV 52 ERalpha 52 progression TTP 52 differentially expressed genes 52 OGTT 52 visceral adiposity 52 liver histology 52 median PFS 52 statistically significant p = 52 gastric cardia 52 DAS# [002] 52 apolipoproteins 52 cytokeratin 52 Doppler sonography 52 HRQL 52 bronchoalveolar lavage 52 quartiles 52 LUTS 52 comorbid depression 52 homozygosity 52 renal tumors 52 semiquantitative 52 multivariate adjusted 52 microvessel 52 postoperative chemotherapy 52 parkinsonism 52 leukocyte counts 52 SLC#A# [002] 52 retrospectively analyzed 52 plasma leptin 52 substudy 52 Main Outcome Measures 52 GSTP1 52 eGFR 52 reach statistical significance 52 APOE ε4 52 cytogenetic abnormalities 52 albuminuria 52 kidney allograft 52 ERBB2 52 carotid plaque 52 CORE OM 52 parous 52 bronchioloalveolar carcinoma 52 prognostic biomarker 52 hip resurfacing arthroplasty 52 germline mutations 52 locoregional disease 52 GABRA2 52 QoL 52 Lymph node 52 composite endpoint 52 serum calcium 52 left ventricular dysfunction 52 pg ml 52 reoperation 52 HBeAg 52 chromosome #p# [002] 52 hypervascular 52 % CI #.#-#.# [005] 52 normal karyotype 51 Insulin sensitivity 51 biopsy Gleason 51 thromboembolic events 51 lymphopenia 51 biventricular repair 51 squamous histology 51 thromboembolic 51 seronegative 51 myocardial viability 51 femoral neck BMD 51 psychosocial variables 51 vitro experiments 51 nonresponders 51 differential gene expression 51 NIHSS 51 undetectable HBV DNA 51 polyp recurrence 51 EBRT 51 perineural invasion 51 subanalysis 51 postoperative morbidity 51 CagA 51 submucosal 51 p = NS 51 FDG uptake 51 diabetes mellitus DM 51 DRD2 51 agonist induced 51 depressive symptom 51 sonographic evaluation 51 postmenopausal hormone 51 C. pneumoniae 51 symptom exacerbation 51 μmol L 51 β = 51 laboratory abnormalities 51 oophorectomy 51 metastatic lymph nodes 51 systolic function 51 HCCs 51 plasma lipids 51 splenic 51 microbleeds 51 postoperative mortality 51 antibody titer 51 pelvic lymphadenectomy 51 statistically significant correlations 51 rebleeding 51 genotypes 51 central corneal thickness 51 serum cotinine 51 affective psychosis 51 secondary efficacy endpoint 51 genotyped 51 variant rs# 51 plain radiographs 51 WOMAC scores 51 Multiple linear regression 51 = #.#-#.# 51 lobular carcinoma 51 cTnT 51 GG genotype 51 extramedullary 51 erythrocyte sedimentation rate 51 prospective longitudinal 51 alkaline phosphatase ALP 51 hyperintensity 51 undergone radical prostatectomy 51 exhaled nitric oxide 51 epithelial ovarian cancer 51 polymorphisms 51 Multivariate analysis revealed 51 Kaplan Meier curve 51 SGRQ 51 FDG PET imaging 51 axillary lymph nodes 51 variant alleles 51 Charlson comorbidity index 51 chest radiographs 51 left ventricular systolic 51 liver metastasis 51 chronicity 51 hematological relapse 51 hematologic toxicity 51 contralateral breast 51 dimensional echocardiography 51 euthymic patients 51 glomerular filtration 51 lipid lowering therapy 51 5 HTTLPR 51 arteriography 51 nonalcoholic steatohepatitis NASH 51 nomogram 51 colorectal carcinoma 51 VKORC1 51 liver biopsies 51 QTcF 51 HRQoL 51 WOMAC pain 51 Kaplan Meier 51 UGT#A# * 51 atheroma volume 51 plasma folate 51 neurocognitive function 51 APOE e4 51 Secondary endpoints 51 plasma selenium 51 papillary renal cell carcinoma 51 carcinoids 51 radiographic findings 51 SSc 51 evaluable 51 RCTs 51 nonischemic 51 echocardiographic parameters 51 histologic findings 51 radiochemotherapy 51 prognostic indicators 51 glomerular filtration rate 51 PCWP 51 leiomyomas 51 prognostic indicator 51 lactate dehydrogenase 51 breast cancer subtypes 51 HER2 overexpression 51 colorectal adenomas 51 hamartomas 51 inflammatory markers 51 CT perfusion 51 thyroid nodule 51 UACR 51 hepatic resection 51 Montgomery Åsberg Depression 51 baseline LDH 51 HIV HCV coinfected 51 antihypertensive medication 51 inverse association 51 pharmacokinetics PK 51 antiretroviral naïve 51 Oncotype DX Recurrence Score 51 differentially expressed 51 APOC3 51 serum leptin 51 dichotomized 51 serum ferritin 51 sonographic findings 51 liver resection 51 Lp PLA 2 51 Immunohistochemical staining 51 scintigraphy 51 antigen PSA levels 51 hydroxyvitamin D levels 51 impaired endothelial 51 adverse perinatal 51 BRCA1 mutations 51 ADCS ADL 51 singleton pregnancies 51 esophageal squamous cell carcinoma 51 penetrance 51 allelic variants 51 EGFR mutation status 51 MTT assay 51 aspartate aminotransferase AST 51 thyroid nodules 51 hippocampal volume 51 primary aldosteronism 51 telomere lengths 51 Predictors 51 BMI waist circumference 51 KRAS mutation status 51 subthreshold depression 51 multivessel disease 51 nulliparous women 51 RECIST criteria 51 Preoperative 51 fasting plasma 51 sonographically 51 ROC curves 51 acute cholecystitis 51 potentially modifiable 51 gene polymorphism 51 HIV seroconversion 51 carotid stenosis 51 Prostate specific antigen 51 Inhibin B 51 Tg mice 51 familial AF 51 virologic responses 50 pentoxifylline 50 thyroid stimulating hormone 50 renal dysfunction 50 pre eclamptic 50 Immunohistochemical 50 hamartoma 50 undergoing radical cystectomy 50 Breslow thickness 50 mg kg dose 50 p = #.# [004] 50 #OHD 50 apolipoprotein B 50 BRAF V#E mutation 50 infarcts 50 socioeconomic status 50 LDL particle 50 TP# mutations 50 microsatellite instability 50 elevated serum creatinine 50 stratifying patients 50 OPCAB 50 adjuvant therapies 50 urinary excretion 50 chemoradiotherapy 50 subtrochanteric 50 cortical activation 50 renal cysts 50 elevated ALT 50 epidural analgesia 50 #.#ng/ml 50 urinary albumin 50 cystoscopic 50 transferrin saturation 50 MLH1 50 CI #.#-#.# [001] 50 renal insufficiency 50 #q# deletion syndrome 50 curative resection 50 malignant lymphoma 50 nondepressed 50 adenoidectomy 50 micrometastases 50 duplex ultrasonography 50 serum GGT 50 serum creatinine 50 stratified 50 SCr 50 LPS induced 50 Observational studies 50 elevated CRP 50 inhibin 50 subclinical hyperthyroidism 50 SHBG levels 50 virological failure 50 vertebral fracture 50 ASCUS 50 VADT 50 bilateral oophorectomy 50 apparent diffusion coefficient 50 PITX2 50 normoxic 50 TKAs 50 anterior temporal 50 serum lipid levels 50 recurrent UTI 50 fosamprenavir 50 RBC folate 50 correlational 50 achieved statistical significance 50 response pCR 50 haplotypes 50 jugular venous 50 Multivariate analysis showed 50 isoprostane 50 LAGB 50 BRCA1 mutation carriers 50 covariance ANCOVA 50 LHRH receptor positive 50 MGUS 50 serum IgE 50 coronary angiography 50 serum triglyceride 50 RE LY trial 50 neurocognitive impairment 50 mammographically 50 serum prostate 50 dose atorvastatin 50 darunavir ritonavir 50 T1a 50 microalbuminuria 50 DAS# scores 50 visceral metastases 50 hsCRP 50 LVEF 50 spontaneous bacterial peritonitis 50 G allele 50 K ras mutations 50 antiphospholipid antibodies 50 BRCA2 mutation carriers 50 interrater reliability 50 inhaled corticosteroid therapy 50 serum biomarker 50 nephron sparing surgery 50 mutated K ras 50 underwent resection 50 % CI #.#-#.# [001] 50 CI -#.# 50 mutant allele 50 nmol 50 comorbid illnesses 50 haplotype 50 CD# expression [002] 50 fractional anisotropy 50 idraparinux 50 thrombocytopenic 50 hemoglobin Hb 50 randomized controlled trials RCTs 50 comorbid anxiety 50 preterm neonates 50 recurrent venous thromboembolism 50 serum triglycerides 50 potentially confounding variables 50 nonoperative treatment 50 adjuvant chemotherapy 50 TIMP 50 Secondary efficacy endpoints 50 invasive carcinoma 50 Reynolds Risk Score 50 basal cell carcinoma BCC 50 DLTs 50 luminal 50 â ‰ ¥ 50 serum creatinine levels 50 neoplasm 50 antithymocyte globulin 50 PSA kinetics 50 prospectively evaluated 50 nonfasting triglyceride levels 50 ligand induced 50 fraternal twin pairs 50 trials RCTs 50 β blocker 50 nonpregnant women 50 chest radiograph 50 lumbar spine BMD 50 BEXXAR Therapeutic Regimen 50 anti JCV antibodies 50 serum parathyroid hormone 50 hippocampal atrophy 50 Histopathological 50 serum BDNF 50 VNTR 50 serum urate levels 50 affective disorders 50 epidemiologic studies 50 waist circumference WC 50 HLA A2 50 thrombophilia 50 neoplasias 50 Stroop task 50 ventricular mass 50 chorioamnionitis 50 macroalbuminuria 50 functional polymorphism 50 mIU L 50 paricalcitol 50 QRS interval 50 homocysteine concentrations 50 stone formers 50 apolipoprotein E gene 50 CLBP 50 calculi 50 meta analysis 50 electrophysiologic 50 CI #.#-#.# [002] 50 tumor necrosis 50 inversely associated 50 partial remissions 50 nonfatal stroke 50 patients evaluable 50 tumorigenicity 50 SHBG 50 tipranavir ritonavir 50 hyperacute 50 poorer prognosis 50 undergoing coronary artery 50 Prognostic factors 50 colonic polyps 50 airway hyperresponsiveness 50 perinatal outcomes 50 hypogonadal 50 longitudinal observational study 50 pericardial effusion 50 baseline CD4 50 metaanalysis 50 oral glucose tolerance 50 umbilical vein 50 Thrombolysis 50 MADRS score 50 LVSD 50 tipranavir r 50 systolic dysfunction 50 desvenlafaxine succinate 50 hyperoxia 50 allele frequency 50 endometrial hyperplasia 50 NIH CPSI 50 carotid bruit 50 ß = 50 pulmonary nodules 50 stenoses 50 epistasis 50 inducible nitric oxide synthase 50 polytherapy 50 HbA 1c levels 50 hepatic enzyme 50 Histological 50 acetabular fracture 50 cerebral infarction 50 EPDS 50 Cystatin C 50 Conclusions 50 GnRH agonist 50 CYP#C# [001] 50 preoperative diagnosis 50 glycoprotein IIb IIIa inhibitors 50 Prognostic significance 50 obstructive coronary 50 bronchoalveolar lavage BAL 50 genetic loci 50 abciximab 50 correlation coefficients 50 HLA DRB1 50 recanalization 50 postoperative 50 Zevalin consolidation 50 serous ovarian cancer 50 CD# expression [001] 50 sonographic appearance

Back to home page